Pfizer stock rises after aligning with Trump on drug pricing
Pfizer's shares climbed on Monday after the company expressed support for former President Donald Trump's proposal to allow imports of lower-priced drugs from Canada. This stance marks a shift for the pharmaceutical giant, which has historically opposed such measures. The move comes amid ongoing debates over U.S. drug costs.
On September 30, 2025, Pfizer's stock experienced a notable uptick during midday trading, rising approximately 3.5% to around $29.50 per share. This surge followed comments from Pfizer executives aligning the company with Donald Trump's long-standing advocacy for importing cheaper prescription drugs from Canada to address high U.S. healthcare costs.
Trump has repeatedly pushed this idea, arguing it would force domestic drugmakers to lower prices. In a recent statement, Pfizer CEO Albert Bourla indicated openness to the policy, saying, 'We are committed to ensuring affordable access to medicines,' according to reports. This position contrasts with the industry's typical resistance, as imports could undercut profits from U.S.-exclusive pricing.
The MarketWatch article highlighted how this agreement provided a 'boost' to Pfizer's 'ailing stock,' which had been under pressure from patent expirations and competitive pressures in the pharmaceutical sector. Shares had declined over 20% year-to-date prior to this news. CNBC's midday stock update confirmed the gains, noting Pfizer (PFE) as one of the biggest movers, alongside mentions of other tickers like SMTC, SPOT, PATH, and CRWV, though the focus remained on pharmaceutical developments.
Background context reveals Trump's proposal dates back to his presidency, but implementation has stalled due to opposition from drug companies citing safety concerns over foreign imports. Pfizer's pivot may signal broader industry adaptation ahead of potential policy shifts, especially with the 2024 election cycle influencing health policy discussions. No immediate regulatory changes were announced, but the stock reaction underscores investor sensitivity to political alignments in the sector.
Analysts view this as a strategic move by Pfizer to mitigate risks from aggressive pricing reforms, potentially improving its public image while safeguarding market position. However, details on the exact scope of support remain limited, with Bourla's remarks emphasizing collaboration rather than full endorsement.